A letter to the editor has been submitted to the Journal by Dr. Darrel P. Francis and colleagues regarding the paper by Bartunek et al. (1). Due to the nature, detail, and length of the letter and the corresponding reply, the editors have made a decision to waive the usual word limit and timelines for letters and replies so as to provide a full airing of the issues for our readers. However, given the length of the material, we have elected to place the letter and reply in the online version of the issue. We encourage readers to access this material and trust that it contributes to the editorial process.
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APPENDIX
For a list of issues regarding C-CURE and the responses of the authors, please see the online version of this issue.
The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE)
We read with interest the recent C-CURE (Cardiopoietic stem Cell therapy in heart failURE) trial (1) of stem cells used for the treatment of heart failure. Completing such a multicenter trial is a great achievement, but applying its findings either to clinical care or future trial design might be premature, as there appear to be some inconsistencies in the data. Discrepancies, if left unresolved, can be problematic (2):
How many patients were randomized? Counts ranged from 45 to 48. The authors' corporate website (3) currently states that randomization was 1:1, but Figure 1 in the paper (1) shows counts close to 1:2; conversely, at AHA 2011, the authors said that randomization was 2:1, but reported counts that were close to 1:1. Can the authors please clarify the randomization ratio? Once randomized to 1 arm, did any patient's data appear under the heading of the opposite arm? Were some patients allocated to arms by routes other than randomization to those arms? Are baseline characteristics and result data regarding the trial arms, as randomized, available?
The primary endpoint was pre-specified to be radionuclide ejection fraction, but its results do not appear in the paper. A
